GoodRx Reports Better Than Expected Q4 Results

GoodRx Holdings, Inc. (NASDAQ:GDRX) reported its Q4 earnings results last week, with EPS of $0.07 coming in better than the Street estimate of $0.05. Revenue was $184.1 million, beating the Street estimate of $178.67 million.

Management provided the initial 2023 guidance, estimating revenue to be in the range of $780-$790 million with a mid-20s adjusted EBITDA margin. The Street expected the company to generate $778 million in revenue with approximately a 24% margin.

For Q1, the company expects revenue in the range of $181-$183 million with a mid-20s margin, mostly in line with the Street estimates.

Management highlighted the new collaboration with Express Scripts which builds in GoodRx discount prices in the pharmacy benefits for all participating Cigna Health Plans with over 10 million lives.